Cost-effectiveness of antipsychotics for outpatients with chronic schizophrenia

International Journal of Clinical Practice

Volumn 61, Issue 12, 2007, Pages 1979-1988

  Obradovic, M ^a   Mrhar, A ^a   Kos, M ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BIPERIDEN; HALOPERIDOL; HALOPERIDOL DECANOATE; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PLACEBO; QUETIAPINE; RISPERIDONE; UNCLASSIFIED DRUG; ZIPRAZIDONE;

ALTERNATIVE MEDICINE; ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; COMPARATIVE STUDY; COMPLIANCE (PHYSICAL); COST; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DRUG SAFETY; ECONOMICS; HEALTH CARE; HOSPITAL PATIENT; HOSPITAL READMISSION; HUMAN; MODEL; OUTCOME ASSESSMENT; OUTPATIENT; PRIORITY JOURNAL; REMISSION; SCHIZOPHRENIA; SENSITIVITY ANALYSIS; THERAPY EFFECT;

AMBULATORY CARE; ANTIPSYCHOTIC AGENTS; CHRONIC DISEASE; COST-BENEFIT ANALYSIS; HOSPITALIZATION; HUMANS; PATIENT COMPLIANCE; PATIENT READMISSION; SCHIZOPHRENIA;

EID: 35948929379     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2007.01431.x     Document Type: Article

References (61)

1. Goldner EM, Hsu L, Waraich P, Somers JM. Prevalence and incidence studies of schizophrenic disorders: a systematic review of the literature. Can J Psychiatry 2002 47 : 833 43.
2. Murray CJL, Lopez AD (eds) Global Burden of Disease. Cambridge, MA : Harvard Univ. Press, 1996.
3. American Psychiatric Association. Practice Guideline for the Treatment of Patients With Schizophrenia, 2nd edn. http://www.psych.org/psych_pract/treatg/ pg/Practice%20Guidelines8904/Schizophrenia_2e.pdf (accessed January 2006).
4. Glazer WM, Ereshefsky L. A pharmacoeconomic model of outpatient antipsychotic therapy in 'revolving door' schizophrenic patients. J Clin Psychiatry 1996 57 : 337 45.
5. Ganguly R, Miller LS, Martin BC. Future employability, a new approach to cost-effectiveness analysis of antipsychotic therapy. Schizophr Res 2003 63 : 111 9.
6. Edwards NC, Locklear JC, Rupnow MF, Diamond RJ. Cost-effectiveness model of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA. Pharmacoeconomics 2005 23 (Suppl. 1 75 89.
7. Garcia-Cabeza I, Gomez JC, Sacristan JA, Edgell E, Gonzalez de Chavez M. Subjective response to antipsychotic treatment and compliance in schizophrenia. A naturalistic study comparing olanzapine, risperidone and haloperidol (EFESO Study). BMC Psychiatry 2001 1 : 7.
8. Gibson PJ, Damler R, Jackson EA, Wilder T, Ramsey JL. The impact of olanzapine, risperidone, or haloperidol on the cost of schizophrenia care in a medicaid population. Value Health 2004 7 : 22 35.
9. Dolder CR, Lacro JP, Dunn LB, Jeste DV. Antipsychotic medication adherence: is there a difference between typical and atypical agents Am J Psychiatry 2002 159 : 103 8.
10. Voruganti L, Cortese L, Owyeumi L et al. Switching from conventional to novel antipsychotic drugs: results of a prospective naturalistic study. Schizophr Res 2002 57 : 201 8.
11. Al-Zakwani IS, Barron JJ, Bullano MF, Arcona S, Drury CJ, Cockerham TR. Analysis of healthcare utilization patterns and adherence in patients receiving typical and atypical antipsychotic medications. Curr Med Res Opin 2003 19 : 619 26.
12. Menzin J, Boulanger L, Friedman M, Mackell J, Lloyd JR. Treatment adherence associated with conventional and atypical antipsychotics in a large state Medicaid program. Psychiatr Serv 2003 54 : 719 23.
13. Diaz E, Neuse E, Sullivan MC, Pearsall HR, Woods SW. Adherence to conventional and atypical antipsychotics after hospital discharge. J Clin Psychiatry 2004 65 : 354 60.
14. Cooper D, Moisan J, Gaudet M, Abdous B, Gregoire JP. Ambulatory use of olanzapine and risperidone: a population-based study on persistence and the use of concomitant therapy in the treatment of schizophrenia. Can J Psychiatry 2005 50 : 901 8.
15. Joyce AT, Harrison DJ, Loebel AD, Ollendorf DA. Impact of atypical antipsychotics on outcomes of care in schizophrenia. Am J Manag Care 2005 11 (Suppl. 8 S254 61.
16. David AS, Adams C. Depot antipsychotic medication in the treatment of patients with schizophrenia: (1) meta-review; (2) patient and nurse attitudes. Health Technol Assess 2001 5 : 1 61.
17. Schooler NR. Relapse and rehospitalization: comparing oral and depot antipsychotics. J Clin Psychiatry 2003 64 (Suppl. 16 14 7.
18. Kane J, Nemec CEA. Adherence Issues and Solutions with Antipsychotic Therapy. http://www.medscape.com/viewprogram/2031 (accessed October 2005; published 25 September 2002).
19. Csernansky JG, Schuchar EK. Relapse and rehospitalisation rates in patients with schizophrenia: effects of second generation antipsychotics. CNS Drugs 2002 16 : 473 84.
20. Weiden PJ, Kozma C, Grogg A, Locklear J. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv 2004 55 : 886 91.
21. Valenstein M, Blow FC, Copeland LA et al. Poor antipsychotic adherence among patients with schizophrenia: medication and patient factors. Schizophr Bull 2004 30 : 255 64.
22. Eaddy M, Grogg A, Locklear J. Assessment of compliance with antipsychotic treatment and resource utilization in a Medicaid population. Clin Ther 2005 27 : 263 72.
23. Olfson M, Mechanic D, Hansell S, Boyer CA, Walkup J, Weiden PJ. Predicting medication noncompliance after hospital discharge among patients with schizophrenia. Psychiatr Serv 2000 51 : 216 22.
24. Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophr Bull 1995 21 : 419 29.
25. Lieberman JA, Stroup TS, McEvoy JP et al. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005 353 : 1209 23.
26. Tran PV, Hamilton SH, Kuntz AJ et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997 17 : 407 18.
27. Namjoshi M, Young C, Huang L, Edgell E, Breier A. Hospitalization rates associated with olanzapine, risperidone, and haloperidol treatment in patients with schizophrenia: results from U.S. randomized controlled trial. Eur Neuropsychopharmacol 2002 12 : 315.
28. Hamilton SH, Edgell ET, Revicki DA, Breier A. Functional outcomes in schizophrenia: a comparison of olanzapine and haloperidol in a European sample. Int Clin Psychopharmacol 2000 15 : 245 55.
29. Tran PV, Dellva MA, Tollefson GD, Wentley AL, Beasley CM Jr. Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses. Br J Psychiatry 1998 172 : 499 505.
30. Csernansky JG, Mahmoud R, Brenner R Risperidone-USA-79 Study Group. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 2002 346 : 16 22.
31. Ascher-Svanum H, Zhu B, Faries D, Ernst FR. A comparison of olanzapine and risperidone on the risk of psychiatric hospitalization in the naturalistic treatment of patients with schizophrenia. Ann Gen Hosp Psychiatry 2004 3 : 11.
32. Dossenbach M, Arango-Davila C, Silva Ibarra H et al. Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. J Clin Psychiatry 2005 66 : 1021 30.
33. Rabinowitz J, Lichtenberg P, Kaplan Z, Mark M, Nahon D, Davidson M. Rehospitalization rates of chronically ill schizophrenic patients discharged on a regimen of risperidone, olanzapine, or conventional antipsychotics. Am J Psychiatry 2001 158 : 266 9.
34. Coley KC, Carter CS, DaPos SV, Maxwell R, Wilson JW, Branch RA. Effectiveness of antipsychotic therapy in a naturalistic setting: a comparison between risperidone, perphenazine, and haloperidol. J Clin Psychiatry 1999 60 : 850 6.
35. Ascher-Svanum H, Zhu B, Faries D, Landbloom R, Swartz M, Swanson J. Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia. BMC Psychiatry 2006 6 : 8.
36. Pigott TA, Carson WH, Saha AR, Torbeyns AF, Stock EG, Ingenito GG Aripiprazole Study Group. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry 2003 64 : 1048 56.
37. Beasley CM Jr., Sutton VK, Hamilton SH et al. Olanzapine Relapse Prevention Study Group. A double-blind, randomized, placebo-controlled trial of olanzapine in the prevention of psychotic relapse. J Clin Psychopharmacol 2003 23 : 582 94.
38. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003 60 : 553 64.
39. Leucht S, Barnes TR, Kissling W, Engel RR, Correll C, Kane JM. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry 2003 160 : 1209 22.
40. Loo H, Poirier-Littre MF, Theron M, Rein W, Fleurot O. Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia. Br J Psychiatry 1997 170 : 18 22.
41. Mortimer A, Martin S, Loo H, Peuskens J SOLIANOL Study Group. A double-blind, randomized comparative trial of amisulpride versus olanzapine for 6 months in the treatment of schizophrenia. Int Clin Psychopharmacol 2004 19 : 63 9.
42. Sechter D, Peuskens J, Fleurot O, Rein W, Lecrubier Y Amisulpride Study Group. Amisulpride vs. risperidone in chronic schizophrenia: results of a 6-month double-blind study. Neuropsychopharmacology 2002 27 : 1071 81.
43. Diaz E, Levine HB, Sullivan MC et al. Use of the Medication Event Monitoring System to estimate medication compliance in patients with schizophrenia. J Psychiatry Neurosci 2001 26 : 325 9.
44. Almond S, Knapp M, Francois C, Toumi M, Brugha T. Relapse in schizophrenia: costs, clinical outcomes and quality of life. Br J Psychiatry 2004 184 : 346 51.
45. Yang YK, Tarn YH, Wang TY et al. Pharmacoeconomic evaluation of schizophrenia in Taiwan: model comparison of long-acting risperidone versus olanzapine versus depot haloperidol based on estimated costs. Psychiatry Clin Neurosci 2005 59 : 385 94.
46. Gladek M. Farmakoekonomski vidiki uporabe klasičnih in atipičnih antipsihotikov pri bolnikih s shizofrenijo. Ljubljana : Diplomska naloga, Univerza v Ljubljani- Fakulteta za farmacijo, 2005.
47. Health Insurance Institute of Slovenia. Price List of Ambulatory Drugs in Solvenia - Dec 2005. http://www.zzzs.si/ZZZS/info/egradiva.nsf/o/ 85FEFE028EB16174C1256DF600371127?OpenDocument (accessed June 2006).
48. Drug Database. Public Health Institute Maribor Drugstores. http://www.zdravila.net/ (accessed October 2005).
49. Davis JM, Chen N. Dose response and dose equivalence of antipsychotics. J Clin Psychopharmacol 2004 24 : 192 208.
50. McKeage K, Plosker GL. Amisulpride: a review of its use in the management of schizophrenia. CNS Drugs 2004 18 : 933 56.
51. Kocmur M, Tavcar R, Zmitek A. Shizofrenija: priporocila in smernice za zdravljenje z zdravili. Ljubljana : Republiski strokovni kolegij za psihiatrijo. Viceversa: slovenske psihiatricne publikacije: prirocniki, 2000.
52. Health Insurance Institute of Slovenia. Average Prices of Health Care Procedures valid from 1st Jul 2005. ZZZS. http://www.zzzs.si/zzzs/pao/izvajalci. nsf/o/07F4858EE380C36FC1257030007E8929 (accessed October 2005).
53. Cantor SB. Cost-effectiveness analysis, extended dominance, and ethics: a quantitative assessment. Med Decis Making 1994 14 : 259 65.
54. Freedman R. Schizophrenia. N Engl J Med 2003 349 : 1738 49.
55. Palmer CS, Revicki DA, Genduso LA, Hamilton SH, Brown RE. A cost-effectiveness clinical decision analysis model for schizophrenia. Am J Manag Care 1998 4 : 345 55.
56. Launois R, Von Der Schulenburg M, Knapp M, Toumi M. Cost-effectiveness of sertindole versus olanzapineor haloperidol: a comprehensive model. Int J Psychiatry Clin Pract 1998, 2 : S79 86.
57. Byrom B, Garrat C. Influence of antipsychotic profile on cost of treatment of schizophrenia: a decision analysis approach. Int J Psychiatry Clin Pract 1998 12 : 129 38.
58. Almond S, O'Donnell O. Cost analysis of the treatment of schizophrenia in the UK. A simulation model comparing olanzapine, risperidone and haloperidol. Pharmacoeconomics 2000 17 : 383 9.
59. Davies A, Langley PC, Keks NA, Catts SV, Lambert T, Schweitzer I. Risperidone versus haloperidol: II. Cost-effectiveness. Clin Ther 1998 20 : 196 213.
60. Palmer CS, Brunner E, Ruiz-Flores LG, Paez-Agraz F, Revicki DA. A cost-effectiveness clinical decision analysis model for treatment of schizophrenia. Arch Med Res 2002 33 : 572 80.
61. Summary of Product Characteristic for haloperidol. Agency for Medicinal Products and Medical Devices of the Republic of Slovenia. http://www.zdravila. net (accessed October 2005).